clinical trial · NCT06958692
A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder
CSPC Ouyi Pharmaceutical Co., Ltd.·phase3·recruiting·n = 388
Major Depressive Disorder (MDD)Dextromethorphan and Bupropion Sustained-Release TabletsPlacebo
brief summary
A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial, aim to evaluate the efficacy and safety of dextromethorphan and bupropion sustained-release tablets in Chinese adult patients with major depressive disorder.
started
Apr 11, 2025
primary completion
Sep 30, 2026
completion
Dec 30, 2026
last updated
May 6, 2025
official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Adult Patients With Major Depressive Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol